<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312467669</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312467669</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Immunological follow-up of patients with neuromyelitis optica: Is there a good biomarker?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Chanson</surname><given-names>J-B</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312467669">1</xref>
<xref ref-type="aff" rid="aff2-0961203312467669">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>de Seze</surname><given-names>J</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312467669">1</xref>
<xref ref-type="aff" rid="aff2-0961203312467669">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Eliaou</surname><given-names>J-F</given-names></name>
<xref ref-type="aff" rid="aff3-0961203312467669">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Vincent</surname><given-names>T</given-names></name>
<xref ref-type="aff" rid="aff3-0961203312467669">3</xref>
<xref ref-type="corresp" rid="corresp1-0961203312467669"/>
</contrib>
</contrib-group>
<aff id="aff1-0961203312467669"><label>1</label>Département de Neurologie, Hôpitaux Universitaires de Strasbourg, France</aff>
<aff id="aff2-0961203312467669"><label>2</label>Laboratoire d’Imagerie et de Neurosciences Cognitives (LINC), Université de Strasbourg-CNRS, France</aff>
<aff id="aff3-0961203312467669"><label>3</label>Département d’Immunologie, Hôpital Saint-Eloi, Centre Hospitalier Universitaire de Montpellier, France</aff>
<author-notes>
<corresp id="corresp1-0961203312467669">Thierry Vincent, Département d'Immunologie, Hôpital Saint-Eloi, CHU de Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier, Cedex 5, France. Email: <email>t-vincent@chu-montpellier.fr</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>3</issue>
<fpage>229</fpage>
<lpage>232</lpage>
<history>
<date date-type="received"><day>18</day><month>10</month><year>2012</year></date>
<date date-type="accepted"><day>18</day><month>10</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012. Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>A serial assessment of biomarkers related to disease activity could be clinically useful in some autoimmune diseases. Neuromyelitis optica (NMO) is a severe inflammatory disease of the optic nerves and spinal cord that can be associated with lupus erythematosus, Sjögren syndrome or myasthenia gravis. In this review, we discuss the existing data on the use of biomarkers of disease activity in NMO. A specific and pathogenic antibody (Ab) directed against aquaporin 4 (AQP4) was recently discovered in this disease. The relapses were frequently accompanied by a rise and immunosuppressive therapy by a decrease in serum anti-AQP4 Ab concentrations. However, this association is not strong enough to justify treatment changes based only on anti-AQP4 Ab level variations. This parameter might be helpful as a longitudinal biomarker but only if a threshold inducing a relapse and justifying a switch in therapy can be established. A link between disease severity and serum cytotoxicity against AQP4-expressing cells was proposed but has not yet been confirmed. Finally, the assessment of T cell immunity against AQP4 and specific cytokines could be future directions for research.</p>
</abstract>
<kwd-group>
<kwd>Neuroimmunity</kwd>
<kwd>neuromyelitis optica</kwd>
<kwd>anti-aquaporin 4 antibody</kwd>
<kwd>biomarker</kwd>
<kwd>follow-up</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203312467669" sec-type="intro"><title>Introduction</title>
<p>The assessment of immunological biomarkers plays an important role in the diagnosis of many inflammatory autoimmune diseases. A link between these biomarkers and disease activity was found in some diseases, such as systemic lupus erythematosus and granulomatosis with polyangiitis.<sup><xref ref-type="bibr" rid="bibr1-0961203312467669">1</xref></sup> However, it is still debated whether the follow-up of these biomarkers could reliably predict the disease course and be helpful for adapting therapy.</p>
<p>Devic’s neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system (CNS) that is characterized by the severity of relapses and their predominance in spinal cord and optic nerves.<sup><xref ref-type="bibr" rid="bibr2-0961203312467669">2</xref></sup> The association of NMO with systemic lupus erythematosus, Sjögren syndrome or myasthenia gravis is not rare.<sup><xref ref-type="bibr" rid="bibr3-0961203312467669">3</xref></sup> An immunosuppressive therapy must be administered as soon as possible and adapted according to the patient’s response.<sup><xref ref-type="bibr" rid="bibr4-0961203312467669">4</xref></sup> In view of the severity of the prognosis and the aggressiveness of the treatments, a reliable biomarker is crucial for diagnosing the disease and adapting therapy. Recently, a specific marker named NMO-IgG was discovered in NMO, directed against aquaporin 4 (AQP4), an astrocytic water channel.<sup><xref ref-type="bibr" rid="bibr5-0961203312467669">5</xref>,<xref ref-type="bibr" rid="bibr6-0961203312467669">6</xref></sup> The pathogenic role of anti-AQP4 antibody (Ab) was demonstrated in vivo by passive transfer experiments in animal models.<sup><xref ref-type="bibr" rid="bibr7-0961203312467669">7</xref>–<xref ref-type="bibr" rid="bibr9-0961203312467669">9</xref></sup> This Ab demonstrated an excellent specificity (&gt;95%) and a sensitivity of between 50% and 90% and was recently included in the revised diagnostic criteria for NMO<italic>.</italic><sup><xref ref-type="bibr" rid="bibr10-0961203312467669">10</xref>,<xref ref-type="bibr" rid="bibr11-0961203312467669">11</xref></sup> After a first clinical event not yet fulfilling the NMO diagnosis criteria, the presence of anti-AQP4 Abs is indicative of a high risk of conversion to NMO and justifies an immunosuppressive therapy.<sup><xref ref-type="bibr" rid="bibr4-0961203312467669">4</xref>,<xref ref-type="bibr" rid="bibr10-0961203312467669">10</xref>,<xref ref-type="bibr" rid="bibr12-0961203312467669">12</xref></sup></p>
<p>These results raised the hope that a follow-up of the anti-AQP4 Ab concentration could allow relapses to be predicted and treatment to be adapted in NMO. In this review, we will discuss existing data about the usefulness of anti-AQP4 Ab and other immunological parameters as potential biomarkers of disease activity for the follow-up of NMO patients.</p>
</sec>
<sec id="sec2-0961203312467669"><title>Anti-AQP4 Ab serum concentration</title>
<p>A first study used the indirect immunofluorescence technique to assess and monitor the presence of NMO-IgG in serial serum samples of four NMO patients. Abs were found more frequently during periods of active disease and became undetectable during the stable disease phase following treatment, suggesting a correlation with disease activity, but no statistical test was performed.<sup><xref ref-type="bibr" rid="bibr13-0961203312467669">13</xref></sup> Quantitative assays were later developed allowing a more accurate measurement of Ab concentrations. Specific reactivity against AQP4 was measured in two studies, with six<sup><xref ref-type="bibr" rid="bibr12-0961203312467669">12</xref></sup> and eight<sup><xref ref-type="bibr" rid="bibr14-0961203312467669">14</xref></sup> patients, respectively. A quantitative enzyme-linked immunosorbent assay (ELISA) test was also used on serial samples from 38 patients.<sup><xref ref-type="bibr" rid="bibr15-0961203312467669">15</xref></sup> These three articles reported that anti-AQP4 Ab concentration decreased in the serum after administration of an immunosuppressive therapy (azathioprine, cyclophosphamide or rituximab) and this decrease was associated with less frequent relapses. The decrease of anti-AQP4 Ab concentration under rituximab therapy was confirmed by other studies that also reported a mild increase just after the first administration, likely caused by B-cell activating factor (BAFF) induction following B-cell depletion.<sup><xref ref-type="bibr" rid="bibr16-0961203312467669">16</xref>,<xref ref-type="bibr" rid="bibr17-0961203312467669">17</xref></sup> A rapid decrease after high-dose intravenous methylprednisolone was also reported.<sup><xref ref-type="bibr" rid="bibr12-0961203312467669">12</xref></sup> The two studies with the largest number of patients found that anti-AQP4 Ab serum concentration correlated with clinical disease activity and that the onset of relapses was paralleled by a rise in serum Ab concentration.<sup><xref ref-type="bibr" rid="bibr14-0961203312467669">14</xref>,<xref ref-type="bibr" rid="bibr15-0961203312467669">15</xref></sup> Furthermore, high anti-AQP4 Ab titers were associated with large cerebral lesions, extensive myelitis and complete blindness in at least one eye.<sup><xref ref-type="bibr" rid="bibr12-0961203312467669">12</xref></sup> However, some important limitations should be pointed out. Many studies found no statistically significant correlation between Ab serum levels and disease activity.<sup><xref ref-type="bibr" rid="bibr12-0961203312467669">12</xref>,<xref ref-type="bibr" rid="bibr15-0961203312467669">15</xref></sup> No clear threshold value suggesting the onset of relapses could be determined because of the high inter- and intra-individual variability.<sup><xref ref-type="bibr" rid="bibr12-0961203312467669">12</xref>,<xref ref-type="bibr" rid="bibr14-0961203312467669">14</xref>,<xref ref-type="bibr" rid="bibr15-0961203312467669">15</xref></sup> An increase in Ab concentration did not always lead to a clinical relapse, and some relapses occurred while the anti-AQP4 Ab level remained relatively low. Moreover, anti-AQP4 Ab concentrations were not correlated with the residual functional impairment or the frequency of relapses.<sup><xref ref-type="bibr" rid="bibr14-0961203312467669">14</xref>,<xref ref-type="bibr" rid="bibr15-0961203312467669">15</xref></sup> We measured the anti-AQP4 Ab serum concentration in serial samples from 10 NMO patients followed at our neurology department and found no statistical correlation with the presence of relapses or the level of clinical impairment (poster P661 of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress in 2011). As previously described, an increase in anti-AQP4 Ab concentration sometimes occurred without clinical changes and, conversely, disease worsening was often not accompanied by an increase in anti-AQP4 Ab levels. Hence, we concluded that at the individual level, changes in anti-AQP4 Ab serum concentration are not suitable as a means of predicting the onset of a relapse and adapting the treatment accordingly.</p>
<sec id="sec3-0961203312467669"><title>Complement-mediated cytotoxicity</title>
<p>It has been demonstrated that anti-AQP4 Abs are predominantly IgG1 and can induce complement-mediated cytotoxicity to AQP4-expressing cells.<sup><xref ref-type="bibr" rid="bibr18-0961203312467669">18</xref></sup> A study including 12 NMO patients showed higher levels of cytotoxicity in the serum of patients with severe relapses compared to those with mild relapses.<sup><xref ref-type="bibr" rid="bibr19-0961203312467669">19</xref></sup> Interestingly, the study found no significant difference between NMO-IgG titers in patients with mild versus severe attacks, which suggests that Ab concentration and complement-mediated cytotoxicity might evolve independently during disease evolution. However, another study including 14 patients and using a quantitative cell-based technique found a marked correlation between anti-AQP4 Ab serum concentration and serum cytotoxicity. The latter parameter was not better correlated with relapses.<sup><xref ref-type="bibr" rid="bibr20-0961203312467669">20</xref></sup> Accordingly, in the 10 patients included in our study, we found no particular correlation between the level of serum cytotoxicity and the presence of relapse or clinical impairment. The level of serum cytotoxicity was highly correlated with the anti-AQP4 Ab serum concentration but neither of these parameters reliably predicted the relapses (poster P661 of the 2011 ECTRIMS Congress).</p>
</sec>
<sec id="sec4-0961203312467669"><title>Other avenues of research</title>
<p>The presence of anti-AQP4 Ab in cerebrospinal fluid (CSF) was demonstrated in some studies.<sup><xref ref-type="bibr" rid="bibr12-0961203312467669">12</xref>,<xref ref-type="bibr" rid="bibr21-0961203312467669">21</xref></sup> However, tolerance breakdown against AQP4 is thought to occur in the periphery, and anti-AQP4 Ab concentrations are usually much higher in the serum than in the CSF.<sup><xref ref-type="bibr" rid="bibr12-0961203312467669">12</xref></sup> Rarely, anti-AQP4 Abs have been described in the CSF of seronegative patients,<sup><xref ref-type="bibr" rid="bibr22-0961203312467669">22</xref></sup> but this seems to have been an exceptional finding.<sup><xref ref-type="bibr" rid="bibr21-0961203312467669">21</xref></sup> Nevertheless, pathogenic processes occur in the CNS, and animal models have clearly demonstrated that peripheral Abs have to cross the blood-brain barrier to be pathogenic.<sup><xref ref-type="bibr" rid="bibr9-0961203312467669">9</xref></sup> Accordingly, high anti-AQP4 Ab concentrations in the CSF seem to be associated with relapses, high serum anti-AQP4 Ab concentrations and blood-CSF barrier dysfunction.<sup><xref ref-type="bibr" rid="bibr21-0961203312467669">21</xref>,<xref ref-type="bibr" rid="bibr23-0961203312467669">23</xref></sup> Interestingly, Dujmovic et al. showed that CSF might be more relevant than serum for the follow-up of anti-AQP4 Ab in NMO patients.<sup><xref ref-type="bibr" rid="bibr23-0961203312467669">23</xref></sup> In this study, the association between anti-AQP4 Ab level changes and the onset of a relapse appeared stronger in CSF than in serum, according to the results of paired CSF-serum samples from 12 patients.<sup><xref ref-type="bibr" rid="bibr23-0961203312467669">23</xref></sup> However, the usefulness of CSF studies in NMO follow-up will likely be limited by the low feasibility of repeated lumbar punctures.</p>
<p>Factors other than anti-AQP4 Ab, such as autoreactive T cells, are likely to play a role in NMO pathophysiology, especially — though not exclusively — in seronegative patients.<sup><xref ref-type="bibr" rid="bibr24-0961203312467669">24</xref>,<xref ref-type="bibr" rid="bibr25-0961203312467669">25</xref></sup> The presence of a T-cell reactivity against AQP4 has been demonstrated in NMO, and its assessment might be interesting but difficult to manage routinely as a biomarker.<sup><xref ref-type="bibr" rid="bibr26-0961203312467669">26</xref></sup> Interleukin (IL)-17 secreting T cells (Th17 and IL-17-secreting CD8(+) T cells) appear to be especially involved in NMO. The assessment of the serum levels of IL-17 and T-cell-polarizing cytokines (IL-6, IL-21 and IL-23) could be helpful for the diagnosis of NMO,<sup><xref ref-type="bibr" rid="bibr27-0961203312467669">27</xref></sup> but the relationship with disease activity and their ability to predict the disease course remain to be evaluated.</p>
<p>Finally, glial fibrillar acidic protein (GFAP) and S100β are released into the CSF during NMO relapses, and their CSF concentrations are correlated with relapse severity.<sup><xref ref-type="bibr" rid="bibr28-0961203312467669">28</xref></sup> A rise in serum GFAP concentration was also reported in NMO versus multiple sclerosis, especially during relapses,<sup><xref ref-type="bibr" rid="bibr29-0961203312467669">29</xref></sup> but a larger study found these changes were not statistically significant.<sup><xref ref-type="bibr" rid="bibr30-0961203312467669">30</xref></sup> Whether the increase of GFAP or S100β levels in CSF or serum could precede the clinical onset of relapses and be used as a predictive tool has not yet been evaluated.</p>
</sec>
</sec>
<sec id="sec5-0961203312467669" sec-type="conclusions"><title>Conclusion</title>
<p>Anti-AQP4 Ab is now well recognized as an important element in diagnosing the disease and establishing a prognosis after a first clinical event.<sup><xref ref-type="bibr" rid="bibr4-0961203312467669">4</xref>,<xref ref-type="bibr" rid="bibr10-0961203312467669">10</xref></sup> Some studies have suggested a link between the concentration of this Ab in the serum and disease activity, especially a decrease during an immunosuppressive treatment and an increase during a relapse. However, this correlation was not strong enough to predict unequivocally the future course of the disease. Thus, according to the existing data, a switch in therapy based only on anti-AQP4 Ab level changes does not seem justified. Further clinical studies with a larger number of patients are needed to determine whether a reliable threshold predicting the onset of a relapse or a poor response to therapy can be established. Other avenues of research, such as T-cell immunity, cytokines and markers of astrocytic damage, also require further investigation to demonstrate their clinical relevance.</p>
</sec>
</body>
<back>
<sec id="sec6-0961203312467669"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec7-0961203312467669"><title>Conflict of interest</title>
<p>The authors have no conflicts of interest to declare.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312467669"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kallenberg</surname><given-names>CG</given-names></name><name><surname>Stegeman</surname><given-names>CA</given-names></name><name><surname>Bootsma</surname><given-names>H</given-names></name><name><surname>Bijl</surname><given-names>M</given-names></name><name><surname>Limburg</surname><given-names>PC</given-names></name></person-group>. <article-title>Quantitation of autoantibodies in systemic autoimmune diseases: Clinically useful?</article-title> <source>Lupus</source> <year>2006</year>; <volume>15</volume>: <fpage>397</fpage>–<lpage>402</lpage>.</citation></ref>
<ref id="bibr2-0961203312467669"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Seze</surname><given-names>J</given-names></name><name><surname>Lebrun</surname><given-names>C</given-names></name><name><surname>Stojkovic</surname><given-names>T</given-names></name><name><surname>Ferriby</surname><given-names>D</given-names></name><name><surname>Chatel</surname><given-names>M</given-names></name><name><surname>Vermersch</surname><given-names>P</given-names></name></person-group>. <article-title>Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2003</year>; <volume>9</volume>: <fpage>521</fpage>–<lpage>525</lpage>.</citation></ref>
<ref id="bibr3-0961203312467669"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pittock</surname><given-names>SJ</given-names></name><name><surname>Lennon</surname><given-names>VA</given-names></name><name><surname>de Seze</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Neuromyelitis optica and non organ-specific autoimmunity</article-title>. <source>Arch Neurol</source> <year>2008</year>; <volume>65</volume>: <fpage>78</fpage>–<lpage>83</lpage>.</citation></ref>
<ref id="bibr4-0961203312467669"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collongues</surname><given-names>N</given-names></name><name><surname>de Seze</surname><given-names>J</given-names></name></person-group>. <article-title>Current and future treatment approaches for neuromyelitis optica</article-title>. <source>Ther Adv Neurol Disord</source> <year>2011</year>; <volume>4</volume>: <fpage>111</fpage>–<lpage>121</lpage>.</citation></ref>
<ref id="bibr5-0961203312467669"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lennon</surname><given-names>VA</given-names></name><name><surname>Kryzer</surname><given-names>TJ</given-names></name><name><surname>Pittock</surname><given-names>SJ</given-names></name><etal/></person-group>. <article-title>IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel</article-title>. <source>J Exp Med</source> <year>2005</year>; <volume>202</volume>: <fpage>473</fpage>–<lpage>477</lpage>.</citation></ref>
<ref id="bibr6-0961203312467669"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lennon</surname><given-names>VA</given-names></name><name><surname>Wingerchuk</surname><given-names>DM</given-names></name><name><surname>Kryzer</surname><given-names>TJ</given-names></name><etal/></person-group>. <article-title>A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis</article-title>. <source>Lancet</source> <year>2004</year>; <volume>364</volume>: <fpage>2106</fpage>–<lpage>2112</lpage>.</citation></ref>
<ref id="bibr7-0961203312467669"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bradl</surname><given-names>M</given-names></name><name><surname>Misu</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo</article-title>. <source>Ann Neurol</source> <year>2009</year>; <volume>66</volume>: <fpage>630</fpage>–<lpage>643</lpage>.</citation></ref>
<ref id="bibr8-0961203312467669"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kinoshita</surname><given-names>M</given-names></name><name><surname>Nakatsuji</surname><given-names>Y</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Neuromyelitis optica: Passive transfer to rats by human immunoglobulin</article-title>. <source>Biochem Biophys Res Commun</source> <year>2009</year>; <volume>386</volume>: <fpage>623</fpage>–<lpage>627</lpage>.</citation></ref>
<ref id="bibr9-0961203312467669"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saadoun</surname><given-names>S</given-names></name><name><surname>Waters</surname><given-names>P</given-names></name><name><surname>Bell</surname><given-names>BA</given-names></name><name><surname>Vincent</surname><given-names>A</given-names></name><name><surname>Verkman</surname><given-names>AS</given-names></name><name><surname>Papadopoulos</surname><given-names>MC</given-names></name></person-group>. <article-title>Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice</article-title>. <source>Brain</source> <year>2010</year>; <volume>133</volume>: <fpage>349</fpage>–<lpage>361</lpage>.</citation></ref>
<ref id="bibr10-0961203312467669"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wingerchuk</surname><given-names>DM</given-names></name><name><surname>Lennon</surname><given-names>VA</given-names></name><name><surname>Pittock</surname><given-names>SJ</given-names></name><name><surname>Lucchinetti</surname><given-names>CF</given-names></name><name><surname>Weinshenker</surname><given-names>BG</given-names></name></person-group>. <article-title>Revised diagnostic criteria for neuromyelitis optica</article-title>. <source>Neurology</source> <year>2006</year>; <volume>66</volume>: <fpage>1485</fpage>–<lpage>1489</lpage>.</citation></ref>
<ref id="bibr11-0961203312467669"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>PJ</given-names></name><name><surname>McKeon</surname><given-names>A</given-names></name><name><surname>Leite</surname><given-names>MI</given-names></name><etal/></person-group>. <article-title>Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays</article-title>. <source>Neurology</source> <year>2012</year>; <volume>78</volume>: <fpage>665</fpage>–<lpage>671</lpage>. <comment>discussion 669</comment>.</citation></ref>
<ref id="bibr12-0961203312467669"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Fujihara</surname><given-names>K</given-names></name><name><surname>Nakashima</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: A study on antibody titre</article-title>. <source>Brain</source> <year>2007</year>; <volume>130</volume>: <fpage>1235</fpage>–<lpage>1243</lpage>.</citation></ref>
<ref id="bibr13-0961203312467669"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weinstock-Guttman</surname><given-names>B</given-names></name><name><surname>Miller</surname><given-names>C</given-names></name><name><surname>Yeh</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica</article-title>. <source>Mult Scler</source> <year>2008</year>; <volume>14</volume>: <fpage>1061</fpage>–<lpage>1067</lpage>.</citation></ref>
<ref id="bibr14-0961203312467669"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jarius</surname><given-names>S</given-names></name><name><surname>Aboul-Enein</surname><given-names>F</given-names></name><name><surname>Waters</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Antibody to aquaporin-4 in the long-term course of neuromyelitis optica</article-title>. <source>Brain</source> <year>2008</year>; <volume>131</volume>: <fpage>3072</fpage>–<lpage>3080</lpage>.</citation></ref>
<ref id="bibr15-0961203312467669"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Li</surname><given-names>XF</given-names></name><etal/></person-group>. <article-title>Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4</article-title>. <source>Mult Scler</source> <year>2012</year>; <volume>18</volume>: <fpage>578</fpage>–<lpage>586</lpage>.</citation></ref>
<ref id="bibr16-0961203312467669"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pellkofer</surname><given-names>HL</given-names></name><name><surname>Krumbholz</surname><given-names>M</given-names></name><name><surname>Berthele</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab</article-title>. <source>Neurology</source> <year>2011</year>; <volume>76</volume>: <fpage>1310</fpage>–<lpage>1315</lpage>.</citation></ref>
<ref id="bibr17-0961203312467669"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakashima</surname><given-names>I</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Cree</surname><given-names>BA</given-names></name><etal/></person-group>. <article-title>Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels</article-title>. <source>J Clin Neurosci</source> <year>2011</year>; <volume>18</volume>: <fpage>997</fpage>–<lpage>998</lpage>.</citation></ref>
<ref id="bibr18-0961203312467669"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hinson</surname><given-names>SR</given-names></name><name><surname>Pittock</surname><given-names>SJ</given-names></name><name><surname>Lucchinetti</surname><given-names>CF</given-names></name><etal/></person-group>. <article-title>Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica</article-title>. <source>Neurology</source> <year>2007</year>; <volume>69</volume>: <fpage>2221</fpage>–<lpage>2231</lpage>.</citation></ref>
<ref id="bibr19-0961203312467669"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hinson</surname><given-names>SR</given-names></name><name><surname>McKeon</surname><given-names>A</given-names></name><name><surname>Fryer</surname><given-names>JP</given-names></name><name><surname>Apiwattanakul</surname><given-names>M</given-names></name><name><surname>Lennon</surname><given-names>VA</given-names></name><name><surname>Pittock</surname><given-names>SJ</given-names></name></person-group>. <article-title>Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells</article-title>. <source>Arch Neurol</source> <year>2009</year>; <volume>66</volume>: <fpage>1164</fpage>–<lpage>1167</lpage>.</citation></ref>
<ref id="bibr20-0961203312467669"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kalluri</surname><given-names>SR</given-names></name><name><surname>Illes</surname><given-names>Z</given-names></name><name><surname>Srivastava</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica</article-title>. <source>Arch Neurol</source> <year>2010</year>; <volume>67</volume>: <fpage>1201</fpage>–<lpage>1208</lpage>.</citation></ref>
<ref id="bibr21-0961203312467669"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jarius</surname><given-names>S</given-names></name><name><surname>Franciotta</surname><given-names>D</given-names></name><name><surname>Paul</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: Frequency, origin, and diagnostic relevance</article-title>. <source>J Neuroinflammation</source> <year>2010</year>; <volume>7</volume>: <fpage>52</fpage>–<lpage>52</lpage>.</citation></ref>
<ref id="bibr22-0961203312467669"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klawiter</surname><given-names>EC</given-names></name><name><surname>Alvarez</surname><given-names>E</given-names><prefix>3rd</prefix></name><name><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>NMO-IgG detected in CSF in seronegative neuromyelitis optica</article-title>. <source>Neurology</source> <year>2009</year>; <volume>72</volume>: <fpage>1101</fpage>–<lpage>1103</lpage>.</citation></ref>
<ref id="bibr23-0961203312467669"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dujmovic</surname><given-names>I</given-names></name><name><surname>Mader</surname><given-names>S</given-names></name><name><surname>Schanda</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders</article-title>. <source>J Neuroimmunol</source> <year>2011</year>; <volume>234</volume>: <fpage>124</fpage>–<lpage>130</lpage>.</citation></ref>
<ref id="bibr24-0961203312467669"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moreh</surname><given-names>E</given-names></name><name><surname>Gartsman</surname><given-names>I</given-names></name><name><surname>Karussis</surname><given-names>D</given-names></name><name><surname>Rund</surname><given-names>D</given-names></name><name><surname>Hiller</surname><given-names>N</given-names></name><name><surname>Meiner</surname><given-names>Z</given-names></name></person-group>. <article-title>Seronegative neuromyelitis optica: Improvement following lymphocytapheresis treatment</article-title>. <source>Mult Scler</source> <year>2008</year>; <volume>14</volume>: <fpage>860</fpage>–<lpage>861</lpage>.</citation></ref>
<ref id="bibr25-0961203312467669"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jarius</surname><given-names>S</given-names></name><name><surname>Ruprecht</surname><given-names>K</given-names></name><name><surname>Wildemann</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients</article-title>. <source>J Neuroinflammation</source> <year>2012</year>; <volume>9</volume>: <fpage>14</fpage>–<lpage>14</lpage>.</citation></ref>
<ref id="bibr26-0961203312467669"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Varrin-Doyer</surname><given-names>M</given-names></name><name><surname>Spencer</surname><given-names>CM</given-names></name><name><surname>Schulze-Topphoff</surname><given-names>U</given-names></name><etal/></person-group>. <article-title>Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter</article-title>. <source>Ann Neurol</source> <year>2012</year>; <volume>72</volume>: <fpage>53</fpage>–<lpage>64</lpage>.</citation></ref>
<ref id="bibr27-0961203312467669"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HH</given-names></name><name><surname>Dai</surname><given-names>YQ</given-names></name><name><surname>Qiu</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse</article-title>. <source>J Clin Neurosci</source> <year>2011</year>; <volume>18</volume>: <fpage>1313</fpage>–<lpage>1317</lpage>.</citation></ref>
<ref id="bibr28-0961203312467669"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Misu</surname><given-names>T</given-names></name><name><surname>Takano</surname><given-names>R</given-names></name><name><surname>Fujihara</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Itoyama</surname><given-names>Y</given-names></name></person-group>. <article-title>Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: An astrocytic damage marker</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>2009</year>; <volume>80</volume>: <fpage>575</fpage>–<lpage>577</lpage>.</citation></ref>
<ref id="bibr29-0961203312467669"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Storoni</surname><given-names>M</given-names></name><name><surname>Petzold</surname><given-names>A</given-names></name><name><surname>Plant</surname><given-names>GT</given-names></name></person-group>. <article-title>The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis</article-title>. <source>PLoS One</source> <year>2011</year>; <volume>6</volume>: <fpage>e23489</fpage>–<lpage>e23489</lpage>.</citation></ref>
<ref id="bibr30-0961203312467669"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Storoni</surname><given-names>M</given-names></name><name><surname>Verbeek</surname><given-names>MM</given-names></name><name><surname>Illes</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Serum GFAP levels in optic neuropathies</article-title>. <source>J Neurol Sci</source> <year>2012</year>; <volume>317</volume>: <fpage>117</fpage>–<lpage>122</lpage>.</citation></ref>
</ref-list>
</back>
</article>